Semustine clinical trials
How each study uses Semustine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Semustine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 4
He Huang (2) · First Affiliated Hospital of Zhejiang University (1) · NSABP Foundation Inc (1)
Often tested with
Tested in the same studies.
Busulfan (3) · Cyclophosphamide (3) · Fludarabine phosphate (2) · Fludarabine (2) · Cytarabine (1) · Thymoglobulin (1) · Cyclosporine (1) · Mycophenolic Acid (1)
Studies
Open first, then newest update. How each study uses Semustine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell TransplantationRecruitingPhase 1He HuangNCT06809712Written as Semustine (MeccNU)
- Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell TransplantationRecruitingPhase 1He HuangNCT06809699Written as Semustine (MeCCNU)
- A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological MalignanciesActive, not recruitingPhase 3First Affiliated Hospital of Zhejiang UniversityNCT04547049Written as Me-CCNU
- Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been Removed By SurgeryCompletedPhase 3NSABP Foundation IncNCT00427570Written as semustine
Given beside what is tested · 2 — Semustine is usual care or a partner of the new treatment
- Outcomes of Patients After Allo-HSCT With Decitabine and NACNot yet recruitingPhase 3The First Affiliated Hospital of Soochow UniversityNCT04945096Written as Semustine
- A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.Status unknownPhase 2Yi LuoNCT04688021Written as Me-CCNU
As the comparator · 1 — what is tested is compared with Semustine
Codes
What other systems call Semustine · ClinicalTrials.gg INT008189
- MeSH (NLM) D012673SemustineOne source ClinicalTrials.gov
- UNII (FDA) 6YY7T1T567SEMUSTINEOne source FDA
- NCI Thesaurus C827SemustineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D012673 | Semustine | One source ClinicalTrials.gov |
| UNII (FDA) | 6YY7T1T567 | SEMUSTINE | One source FDA |
| NCI Thesaurus | C827 | Semustine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.